Stockscreener 앱 받기
87.83
0.66%
-0.58
시간 외 거래:
87.91
0.08
+0.09%
전일 마감가:
$88.41
열려 있는:
$88.145
하루 거래량:
11.27M
Relative Volume:
0.84
시가총액:
$152.98B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
24.47
EPS:
3.5895
순현금흐름:
$7.38B
1주 성능:
-0.95%
1개월 성능:
+0.48%
6개월 성능:
-29.85%
1년 성능:
-33.96%
1일 변동 폭
$87.21
$88.59
1주일 범위
$87.21
$91.58
52주 변동 폭
$81.97
$139.06
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
87.83 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
304.69 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.27 | 101.56B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.33 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.88 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
ABT Reiterates by Piper Sandler -- Price Target Maintained at $1 - GuruFocus
Similac survey: 80% of young parents feel pressure to be perfect online - Stock Titan
Piper Sandler reiterates Abbott Labs stock rating on growth outlook By Investing.com - Investing.com Canada
Piper Sandler reiterates Abbott Labs stock rating on growth outlook - Investing.com
Abbott Laboratories earnings calendar builds toward mid-July, shares on NYSE ahead of Q2 update - AD HOC NEWS
How to Approach Abbott Stock Following Its Sharp YTD Decline? - TradingView
5 Dividend Stocks to Buy and Hold Forever - The Motley Fool
Abbott Laboratories (ABT) Stock Could Be 24% Below Fair Value Before Earnings - simplywall.st
Should You Buy Abbott Labs Stock Hand Over Fist Before July 16? - The Motley Fool
3 US Dividend Growth Stocks With Balance Sheet And Payout Focus - simplywall.st
Whistleblower Alleges Medical Giant Bribed Hawaiʻi Provider - Honolulu Civil Beat
Citi Believes Abbott (ABT) Shares are Undervalued Relative to Business Segments - Insider Monkey
Abbott Laboratories Raised Prices, Prompting Sales Slump - WSJ
Ultrahuman M2 Live: Glucose Tracking Without a Prescription Using Abbott's Lingo Launches in the U.S. - Basic Tutorials
Why Abbott’s Libre Sense glucose sport biosensor keeps endurance athletes wired in - AD HOC NEWS
Abbott Laboratories director John Stratton buys $173,640 in shares - Investing.com
Director at Abbott (NYSE: ABT) buys 2,000 shares in open market - Stock Titan
Abbott Laboratories StockChart focus as shares test support - AD HOC NEWS
Ultrahuman Launches M2 Live in U.S. With Abbott Lingo™ CGM Integration - Digital Health News
Ultrahuman launches M2 Live with Abbott's Lingo glucose sensor - t2ONLINE
Abbott Laboratories stock underperforms Wednesday when compared to competitors - MarketWatch
ABT Stock Quote Price and Forecast - CNN
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott's CGM Growth Story Stays Intact Despite Q1 Moderation - Yahoo Finance
Abbott Laboratories Stock Capital Return Hits $28 Bil - Trefis
Julie Johnson from Texas’s 32nd District Sells Shares in Abbott Laboratories and Accenture - Investing.com
Big Claims, Little Kids: Recent SDNY Decision Highlights Risks in Advertising (via Passle) - Frankfurt Kurnit Klein & Selz
The Hormuz Reopening Trade: These 20 Large-Cap Stocks Still Haven't Caught Up To Pre-War Levels - Benzinga
Texas Rep. Julie Johnson Sold Up to $30K Worth of Abbott Laboratories Stock - Benzinga
How Investors May Respond To Abbott (ABT) Dividend And CE Mark For Dual Glucose‑Ketone Sensor - Yahoo Finance
Can S&P 500 Healthcare Giant Abbott Boost Growth With Libre Duo? - Kalkine Media
How Investors Are Reacting To Abbott (ABT) Pairing Libre Duo Launch With Its Latest Dividend Approval - simplywall.st
Abbott Laboratories (ABT): One of the Best Bargain Stocks to Buy in June - Insider Monkey
Abbott Laboratories Stock (US0028241000): Quiet trading day keeps healthcare name in focus - AD HOC NEWS
Is Abbott (ABT) the Best Longevity Stock to Buy Now? - Insider Monkey
Abbott Laboratories (ABT) Announces Quarterly Dividend of $0.63 - GuruFocus
Abbott Laboratories declares $0.63 dividend - MSN
Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch
Abbott Laboratories Keeps Quarterly Dividend at $0.63 a Share, Payable Aug. 17 to Holders of Record as of July 15 - marketscreener.com
Abbott Laboratories Declares Quarterly Cash Dividend, Payable on August 17, 2026 - marketscreener.com
Abbott recalls heart device monitoring system due to malfunction risk - Cardiovascular Business
Abbott Laboratories Stock (US0028241000): Valuation metrics in focus for S&P 500 healthcare name - AD HOC NEWS
Abbott Laboratories Stock 12‑Month Price Target Cut to $115.5, Implies 29% Upside - TradingView
BofA Securities Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $102 - 富途牛牛
BofA Adjusts Price Target on Abbott Laboratories to $102 From $120 - marketscreener.com
Abbott Laboratories seen as strong buy with 21.8–39.4% upside amid undervaluation and growth prospects. - Pluang
Abbott Laboratories (ABT) Stock Valuation Check After Recent Mixed Performance - simplywall.st
Abbott Laboratories $ABT Shares Bought by Parnassus Investments LLC - MarketBeat
IFM Investors Pty Ltd Has $45.53 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Remains Structurally Undervalued (NYSE:ABT) - Seeking Alpha
Abbott Labs is heavily oversold, says Powers Advisory Group's Matt Powers - MSN
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.01%
자본화:
|
볼륨(24시간):